MedTrace Logo

A Study of LY3039478 in Participants With Advanced Cancer

NCT01695005 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 247

Last updated 2025-12-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find a recommended dose level of LY3039478 that can safely be taken by participants with advanced cancer or cancer that has spread to other parts of the body, including but not limited to lymphoma. The study will also explore changes to various markers in blood cells and tissue. Finally, the study will help to document any tumor activity this drug may have.

Conditions

  • Neoplasms
  • Neoplasm Metastasis
  • Lymphoma

Interventions

DRUG

LY3039478

Administered orally

DRUG

Prednisone

Administered orally

Sponsors & Collaborators

Principal Investigators

  • 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2018-06-26
Completion
2018-06-26
FDA Drug
Yes

Countries

  • United States
  • Denmark
  • France
  • Germany
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01695005 on ClinicalTrials.gov